Regeneron Pharmaceuticals Inc REGN:NASDAQ

Last Price$301.43Cboe Real-Time Last Sale as of 2:19PM ET 7/17/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+3.06(1.03%)
Bid (Size)$301.45 (100)
Ask (Size)$301.77 (17)
Day Low / High$297.19 - 303.30
Volume300.0 K

View Biotechnology IndustryPeer Comparison as of 07/17/2019


Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $301.43
Change: +3.06 (1.03%)
Volume: 300.0 K
2:19PM ET 7/17/2019

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $124.55
Change: +1.73 (1.41%)
Volume: 981.6 K
2:21PM ET 7/17/2019

Agilent Technologies Inc ( NYSE )

Price: $69.89
Change: -0.06 (0.09%)
Volume: 1.3 M
2:21PM ET 7/17/2019

Illumina Inc ( NASDAQ )

Price: $304.23
Change: +1.93 (0.64%)
Volume: 797.4 K
2:21PM ET 7/17/2019

Biogen Inc ( NASDAQ )

Price: $230.95
Change: -0.60 (0.26%)
Volume: 529.3 K
2:16PM ET 7/17/2019

Read more news Recent News

S&P 500 Movers: Cigna Jumps 12%, Leads Gainers; Iron Mountain Slumps 7%
11:55AM ET 7/11/2019 MT Newswires

S&P 500 Top % Movers as of 11:50 am ET Gainers CI, +11.8% CVS, +5.5% UNH, +5% NVDA, +4.3% ANTM, +4.1% Losers IRM, -6.6% FAST, -5.2% LLY, -4.1% ...

S&P 500 Movers: Unum Sinks 5%, Leads Losers; Align Technology Climbs 4%
12:04PM ET 7/10/2019 MT Newswires

S&P 500 Top % Movers as of 12:02 am ET Gainers ALGN, +4.2% MU, +3.7% DVA, +4.0% WDC, +3.9% STX, +3.5% Losers UNM, -4.5% MYL, -4.4% REGN, -3.7% ...

Regeneron Pharma, Sanofi Get European Approval for Libtayo for Advanced Cell Carcinoma
2:56PM ET 7/01/2019 MT Newswires

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said on Monday the European Commission has granted conditional marketing authorization for Libtayo for...

European Regulator Recommends Approval of Regeneron Pharmaceuticals' Atopic Dermatitis Drug in Adolescents
7:43AM ET 6/28/2019 MT Newswires

Regeneron Pharmaceuticals (REGN) and Sanofi said pre-market Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has...

View all Commentary and Analysis

Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs
10:20AM ET 7/17/2019 Zacks

Inovio (INO) stops the phase I/II study on INO-5401 for advanced bladder cancer and cuts its...

Healthcare And Biotechnology Dashboard - Update
8:43PM ET 7/16/2019 Seeking Alpha

Oakmark Global Select Fund: Second Quarter 2019
9:28PM ET 7/15/2019 Seeking Alpha

Oakmark Equity And Income Fund: Second Quarter 2019
1:51PM ET 7/15/2019 Seeking Alpha

Company Profile

Business DescriptionRegeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY. View company web site for more details
Address777 Old Saw Mill River Road
Tarrytown, New York 10591-6707
Number of Employees7,400
Recent SEC Filing06/19/20198-K
Co-President, Chief Executive Officer & DirectorLeonard S. Schleifer
Co-President, Director & Chief Scientific OfficerGeorge Damis Yancopoulos
Chief Financial Officer & Executive VP-FinanceRobert E. Landry
Chief Compliance Officer & Senior Vice PresidentBeth F. Levine

Company Highlights

Price Open$297.26
Previous Close$298.37
52 Week Range$287.66 - 442.00
Market Capitalization$32.5 B
Shares Outstanding107.7 M
SectorHealth Technology
Next Earnings Announcement08/06/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings14.12
Earnings per Share$21.12
Beta vs. S&P 500N/A
Revenue$6.7 B
Net Profit Margin35.13%
Return on Equity29.20%

Analyst Ratings as of 07/05/2019

Consensus RecommendationConsensus Icon
Powered by Factset